CellDetect® Bladder is an innovative urinary marker for the early detection of bladder cancer in urine specimens. Combining color and morphology, CellDetect® is particularly useful for the detection of low-grade tumors. It was also shown to have higher sensitivity than other current diagnostic methods for all bladder cancer grades, making it an effective early indicator of recurrence.
Micromedic: Leading the Path to Introducing Novel Cancer Diagnostic Tools
Micromedic Technologies Ltd. is a public company traded on the Tel Aviv Stock Exchange (MCTC), focusing on the development and commercialization of cancer diagnostic products.
Micromedic focuses on the development and commercialization of innovative in vitro diagnostic solutions for early cancer detection. Particularly, CellDetect® is a new-generation cytopathological staining platform for the improved diagnosis of early-stage bladder cancer tumors. As opposed to standard histochemical stains which only rely on morphology, CellDetect® uses both color and morphology in order to differentiate between normal and malignant cells in urine specimens. This color feature dramatically enhances the diagnostic accuracy across all cancer stages, affording high sensitivity for low-grade tumors. Using equipment and processes available in all pathology laboratories, CellDetect® is also applicable to other types of cancers.